MX342879B - Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen. - Google Patents
Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen.Info
- Publication number
- MX342879B MX342879B MX2013001201A MX2013001201A MX342879B MX 342879 B MX342879 B MX 342879B MX 2013001201 A MX2013001201 A MX 2013001201A MX 2013001201 A MX2013001201 A MX 2013001201A MX 342879 B MX342879 B MX 342879B
- Authority
- MX
- Mexico
- Prior art keywords
- same
- quinoline derivatives
- inhibitors containing
- melk inhibitors
- melk
- Prior art date
Links
- 229940124787 MELK inhibitor Drugs 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36951910P | 2010-07-30 | 2010-07-30 | |
| PCT/US2011/045792 WO2012016082A1 (en) | 2010-07-30 | 2011-07-28 | Quinoline derivatives and melk inhibitors containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013001201A MX2013001201A (es) | 2013-04-03 |
| MX342879B true MX342879B (es) | 2016-10-14 |
Family
ID=45530500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013001201A MX342879B (es) | 2010-07-30 | 2011-07-28 | Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9120749B2 (enExample) |
| EP (1) | EP2597955B1 (enExample) |
| JP (1) | JP5849303B2 (enExample) |
| KR (1) | KR101826382B1 (enExample) |
| CN (1) | CN103153063B (enExample) |
| AU (1) | AU2011282588B2 (enExample) |
| BR (1) | BR112013002182B8 (enExample) |
| CA (1) | CA2806332C (enExample) |
| DK (1) | DK2597955T3 (enExample) |
| ES (1) | ES2565627T3 (enExample) |
| IL (1) | IL223871A (enExample) |
| MX (1) | MX342879B (enExample) |
| RU (1) | RU2582610C2 (enExample) |
| SG (2) | SG187633A1 (enExample) |
| TW (1) | TWI532483B (enExample) |
| WO (1) | WO2012016082A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130225524A1 (en) * | 2010-11-05 | 2013-08-29 | Deping Chai | Chemical Compounds |
| CN104968345B (zh) * | 2012-01-19 | 2018-05-08 | 肿瘤疗法科学股份有限公司 | 1,5-萘啶衍生物和含1,5-萘啶衍生物的melk抑制剂 |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| US10254283B2 (en) | 2013-11-12 | 2019-04-09 | Dana-Farber Cancer Institute, Inc. | Biomarker for MELK activity and methods of using same |
| JP6535007B2 (ja) | 2013-12-20 | 2019-06-26 | インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ | 新規ピペリジンカルボキサミド化合物、その調製方法及び使用 |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| JP6559785B2 (ja) * | 2014-12-15 | 2019-08-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ｅｇｆｒ及びｐｉ３ｋの小分子阻害剤 |
| EP3265093A4 (en) | 2015-03-04 | 2018-11-07 | Dana-Farber Cancer Institute, Inc. | Tricyclic kinase inhibitors of melk and methods of use |
| MX382355B (es) | 2015-04-10 | 2025-03-13 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos. |
| EP3283462B1 (en) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Fused-tricyclic inhibitors of kras and methods of use thereof |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| CN108026046B (zh) * | 2015-07-22 | 2021-12-21 | 亚瑞克西斯制药公司 | 取代的喹唑啉化合物及其作为g12c突变体kras、hras和/或nras蛋白质的抑制剂的用途 |
| WO2017015562A1 (en) * | 2015-07-22 | 2017-01-26 | Araxes Pharma Llc | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
| TW201718536A (zh) * | 2015-08-03 | 2017-06-01 | 必治妥美雅史谷比公司 | 可作為ＴＮＦα調節劑之雜環化合物 |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
| EP3377481A1 (en) | 2015-11-16 | 2018-09-26 | Araxes Pharma LLC | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| CN108779116A (zh) * | 2015-12-22 | 2018-11-09 | 生命医药公司 | 多发性内分泌瘤蛋白-mll相互作用的抑制剂 |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| AU2017296392B2 (en) * | 2016-07-14 | 2020-09-24 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| IL264826B2 (en) | 2016-08-31 | 2024-06-01 | Oncotherapy Science Inc | Monoclonal antibody against melk and utilization thereof |
| EP3519402A1 (en) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| WO2018119039A1 (en) * | 2016-12-23 | 2018-06-28 | Felicitex Therapeutics, Inc. | Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases |
| US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| CN110869358A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
| CN110831933A (zh) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | 喹唑啉衍生物作为突变kras、hras或nras的调节剂 |
| JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
| EP3658560A4 (en) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | SOMATOSTAT IN MODULATORS AND USES THEREOF |
| MA51625B1 (fr) | 2018-01-17 | 2022-07-29 | Crinetics Pharmaceuticals Inc | Procédé de production de modulateurs de somatostatine |
| EP3807248A4 (en) * | 2018-05-29 | 2021-10-27 | Council of Scientific and Industrial Research | BICYCLIC TOPOISOMERASE I INHIBITOR COMPOUNDS, THEIR PREPARATION AND USE |
| BR112021001709A2 (pt) | 2018-08-01 | 2021-05-04 | Araxes Pharma Llc | compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer |
| CN109705037A (zh) * | 2019-01-24 | 2019-05-03 | 广西师范大学 | 4-氨基喹啉-3-甲酸酯衍生物及其制备方法和应用 |
| CN109651355A (zh) * | 2019-01-24 | 2019-04-19 | 广西师范大学 | 3-(2-苯并五元杂环)-4-(3-二甲胺丙氨基)喹啉衍生物及其制备方法和应用 |
| US12486234B2 (en) | 2019-04-24 | 2025-12-02 | Children's Medical Center Corporation | PAPD5 inhibitors and methods of use thereof |
| US12617767B2 (en) | 2019-07-17 | 2026-05-05 | Crinetics Pharmaceuticals, Inc. | Crystalline forms of somatostatin modulators |
| US11926632B2 (en) | 2020-06-22 | 2024-03-12 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
| WO2022015974A2 (en) * | 2020-07-15 | 2022-01-20 | St. Jude Children's Research Hospital, Inc. | Substituted 4-(3-aminoprop-1-yl)aminoquinoline analogs as modulators of melanoma-associated antigen 11 ubiquitin ligase |
| WO2022055880A1 (en) | 2020-09-09 | 2022-03-17 | Crinetics Pharmaceuticals, Inc. | Formulations of a somatostatin modulator |
| CA3195589A1 (en) * | 2020-10-21 | 2022-04-28 | Marion Lanier | Modulators of mas-related g-protein receptor x2 and related products and their use |
| US20240239764A1 (en) | 2020-12-22 | 2024-07-18 | Mekanistic Therapeutics | Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors |
| WO2024220236A2 (en) * | 2023-04-21 | 2024-10-24 | University Of Georgia Research Foundation, Inc. | Hydroxylamine-based bcr-abl1 inhibitors for treatment of cancer |
| WO2025064853A1 (en) * | 2023-09-20 | 2025-03-27 | Momentum Therapeutics, Inc. | Ripk3 inhibitors and methods of use |
| AR134834A1 (es) * | 2024-01-05 | 2026-04-15 | Dewpoint Therapeutics Inc | Compuestos de aminoquinolina y sus usos |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1168801A (en) * | 1966-05-13 | 1969-10-29 | May & Baker Ltd | Quinoline Derivatives |
| US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| TW200423938A (en) * | 2003-02-21 | 2004-11-16 | Wyeth Corp | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
| MXPA05012839A (es) | 2003-05-27 | 2006-05-17 | Pfizer Prod Inc | Quinazolinas y pirido[3,4-d] pirimidinas como inhibidores de receptores tirosina quinasa. |
| EP1786925B1 (en) | 2004-08-10 | 2010-12-08 | Oncotherapy Science, Inc. | Genes and polypeptides relating to breast cancers |
| JP5109131B2 (ja) | 2005-02-10 | 2012-12-26 | オンコセラピー・サイエンス株式会社 | 膀胱癌を診断する方法 |
| EP2295570A1 (en) | 2005-07-27 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
| WO2007056163A2 (en) * | 2005-11-03 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| MX2008013212A (es) * | 2006-04-14 | 2008-10-22 | Astrazeneca Ab | 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r. |
| WO2007139496A1 (en) | 2006-05-30 | 2007-12-06 | Clanotech Ab | Quinoline derivatives acting as tyrosine kinase inhibitors |
| WO2008023841A1 (en) | 2006-08-25 | 2008-02-28 | Oncotherapy Science, Inc. | Breast cancer-associated gene, melk, and its interactions with bcl-g |
| TW200829555A (en) * | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| CA2672327A1 (en) | 2006-11-30 | 2008-06-05 | Genentech, Inc. | Aza-indolyl compounds and methods of use |
| CN100540551C (zh) | 2007-02-01 | 2009-09-16 | 中国药科大学 | 喹啉衍生物、其制备方法及其医药用途 |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US20100056524A1 (en) * | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
| EP2303890A4 (en) * | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
| MY162604A (en) | 2009-08-17 | 2017-06-30 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| CN104968345B (zh) * | 2012-01-19 | 2018-05-08 | 肿瘤疗法科学股份有限公司 | 1,5-萘啶衍生物和含1,5-萘啶衍生物的melk抑制剂 |
-
2011
- 2011-07-28 WO PCT/US2011/045792 patent/WO2012016082A1/en not_active Ceased
- 2011-07-28 RU RU2013108865/04A patent/RU2582610C2/ru active
- 2011-07-28 SG SG2013006903A patent/SG187633A1/en unknown
- 2011-07-28 JP JP2013523213A patent/JP5849303B2/ja active Active
- 2011-07-28 ES ES11813209.1T patent/ES2565627T3/es active Active
- 2011-07-28 MX MX2013001201A patent/MX342879B/es active IP Right Grant
- 2011-07-28 BR BR112013002182A patent/BR112013002182B8/pt active IP Right Grant
- 2011-07-28 AU AU2011282588A patent/AU2011282588B2/en active Active
- 2011-07-28 KR KR1020137005377A patent/KR101826382B1/ko active Active
- 2011-07-28 SG SG10201505951VA patent/SG10201505951VA/en unknown
- 2011-07-28 EP EP11813209.1A patent/EP2597955B1/en active Active
- 2011-07-28 CN CN201180047405.5A patent/CN103153063B/zh active Active
- 2011-07-28 DK DK11813209.1T patent/DK2597955T3/en active
- 2011-07-28 CA CA2806332A patent/CA2806332C/en active Active
- 2011-07-28 US US13/813,134 patent/US9120749B2/en active Active
- 2011-07-29 TW TW100126942A patent/TWI532483B/zh active
-
2012
- 2012-12-25 IL IL223871A patent/IL223871A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US9120749B2 (en) | 2015-09-01 |
| KR101826382B1 (ko) | 2018-02-06 |
| WO2012016082A1 (en) | 2012-02-02 |
| AU2011282588B2 (en) | 2016-01-07 |
| MX2013001201A (es) | 2013-04-03 |
| DK2597955T3 (en) | 2016-03-14 |
| BR112013002182A2 (pt) | 2016-05-31 |
| EP2597955A1 (en) | 2013-06-05 |
| EP2597955A4 (en) | 2014-02-19 |
| EP2597955B1 (en) | 2016-01-20 |
| TW201208686A (en) | 2012-03-01 |
| CA2806332C (en) | 2017-11-14 |
| SG10201505951VA (en) | 2015-08-28 |
| BR112013002182B8 (pt) | 2023-02-28 |
| KR20130094312A (ko) | 2013-08-23 |
| SG187633A1 (en) | 2013-03-28 |
| RU2013108865A (ru) | 2014-09-10 |
| JP2013532727A (ja) | 2013-08-19 |
| AU2011282588A1 (en) | 2013-03-21 |
| CN103153063B (zh) | 2016-02-17 |
| CA2806332A1 (en) | 2012-02-02 |
| HK1184331A1 (zh) | 2014-01-24 |
| RU2582610C2 (ru) | 2016-04-27 |
| JP5849303B2 (ja) | 2016-01-27 |
| ES2565627T3 (es) | 2016-04-06 |
| TWI532483B (zh) | 2016-05-11 |
| IL223871A (en) | 2016-11-30 |
| US20130217671A1 (en) | 2013-08-22 |
| CN103153063A (zh) | 2013-06-12 |
| BR112013002182B1 (pt) | 2022-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013001201A (es) | Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen. | |
| MX366983B (es) | Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen. | |
| IN2015DN00598A (enExample) | ||
| MY163187A (en) | Novel imidazo-oxazine compound or salt thereof | |
| EP2566477A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS | |
| MX345552B (es) | Compuestos heterocíclicos útiles para inhibición de cinasa. | |
| PH12015502031B1 (en) | Tetrahydropyrrolothiazine compounds | |
| IN2014MN02574A (enExample) | ||
| IN2015DN00960A (enExample) | ||
| CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| CR20120637A (es) | Triazolopiridinas sustituidas | |
| EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
| CR20130539A (es) | Triazolopiridinas | |
| IN2015DN00446A (enExample) | ||
| MX2015017156A (es) | Inhibidores de bace. | |
| IN2014DN07996A (enExample) | ||
| MX353190B (es) | Derivados de isoquinolina y naftiridina. | |
| MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
| MX2015007309A (es) | Derivado de hidantoina. | |
| IN2014DN10669A (enExample) | ||
| AU2013347232A8 (en) | 3-Aminocyclopentane carboxamide derivatives | |
| UY33905A (es) | Inhibidores de la catepsina c | |
| MX342311B (es) | Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl). | |
| MX2013013021A (es) | Nuevos compuestos de hexahidropirroloimidazolona. | |
| UA86566U (en) | N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |